Klaus Dembowsky
Amministratore Delegato presso amcure GmbH
Profilo
Klaus Dembowsky is currently the Chief Executive Officer at amcure GmbH.
Previously, he held the position of Chief Executive Officer at Speedel Pharma AG.
He also served as the Chief Medical Officer & Medical Director at Spexis Ltd.
and as a Manager at Bayer AG.
Additionally, he was the Vice President-Drug Discovery at Ingenium Pharmaceuticals GmbH.
Dr. Dembowsky earned a doctorate degree from Ruprecht-Karls-Universität Heidelberg in 1982.
Posizioni attive di Klaus Dembowsky
| Società | Posizione | Inizio |
|---|---|---|
amcure GmbH
 amcure GmbH BiotechnologyHealth Technology amcure GmbH develops active ingredients for the treatment of angiogenesis-related diseases. It offers a peptide based substance, that targets the tumor specific co-receptors. The company was founded by Matthias Klaften and Alexandra Matzke on December 14, 2011 and is headquartered in Eggenstein-Leopoldshafen, Germany. | Amministratore Delegato | - |
Precedenti posizioni note di Klaus Dembowsky
| Società | Posizione | Fine |
|---|---|---|
| SPEXIS AG | Direttore Tecnico/Scientifico/R&S | - |
| BAYER AG | Corporate Officer/Principal | - |
Ingenium Pharmaceuticals GmbH
 Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Corporate Officer/Principal | - |
Speedel Pharma AG
 Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Amministratore Delegato | - |
Formazione di Klaus Dembowsky
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BAYER AG | Health Technology |
| SPEXIS AG | Health Technology |
| Aziende private | 3 |
|---|---|
Ingenium Pharmaceuticals GmbH
Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Commercial Services |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Health Technology |
amcure GmbH
amcure GmbH BiotechnologyHealth Technology amcure GmbH develops active ingredients for the treatment of angiogenesis-related diseases. It offers a peptide based substance, that targets the tumor specific co-receptors. The company was founded by Matthias Klaften and Alexandra Matzke on December 14, 2011 and is headquartered in Eggenstein-Leopoldshafen, Germany. | Health Technology |
- Borsa valori
- Insiders
- Klaus Dembowsky
